Abstract
1413
Objectives To evaluate the role of fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for staging or restaging of renal cell carcioma (RCC) in patients who had suspected lesions in computed tomography (CT) for distant metastasis and/or local recurrence.
Methods A total of 24 patients (15M,9F; mean age: 59±9 years) who were referred to perform 18F-FDG PET/CT for staging or restaging of RCC (5 staging, 19 restaging) were included in this study. All patients had suspected lesions with thoracal and/or abdominal CT for local recurrence or distant metastasis before PET/CT. 18F-FDG PET/CT findings were compared with CT findings.
Results There was no pathologic 18F-FDG uptake in 10/24 (42%) patients. In the remaining 14/24 (58%) patients, 7/15 patients had concordant and 7/15 had discordant findings with CT. In 5/7 patients, PET/CT was demonstrated more lesions than CT. In 18F-FDG PET/CT, false positive (FP) and false negative (FN) findings were found in reactive mediastinal lymph node and milimetric lung nodules, respectively. In CT, FP findings were found in liver, abdominal lymph nodes, surrenal, lung and plevral effusion. FN finding was found in spleen. According to these findings sensitivity and specificity of 18F-FDG PET/CT in the detection of disease recurrence in RCC patients were calculated as 97% and 89% respectively.
Conclusions 18F-FDG PET/CT is more sensitive than CT in staging or restaging of RCC in patients who had suspected lesions in CT for distant metastasis and/or local recurrence except milimetric lung nodules and reactive mediastinal lymph nodes